CytoDyn (CYDY) Cash from Financing Activities (2010 - 2026)

CytoDyn (CYDY) has 17 years of Cash from Financing Activities data on file, last reported at $16.2 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 77004.76% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $17.2 million (up 31.29% YoY) and the FY2025 annual result came in at $10.9 million, down 7.61% from the prior year.
• Cash from Financing Activities advanced to $16.2 million in Q1 2026, from -$121000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $16.2 million in Q1 2026 to a low of -$121000.0 in Q3 2025.
• A 5-year average of $5.4 million and a median of $3.6 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities plunged 101.25% — and 2026, when it surged 77004.76%.
• Tracing CYDY's Cash from Financing Activities over 5 years: stood at $2.3 million in 2022, then plunged by 71.97% to $654000.0 in 2023, then soared by 1378.13% to $9.7 million in 2024, then sank by 101.25% to -$121000.0 in 2025, then surged by 13481.82% to $16.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $16.2 million (Q1 2026), -$121000.0 (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.